Drugs and Devices

FDA approves new drug for cystic fibrosis

On July 2, the U.S. Food and Drug Administration (FDA) approved Orkambi (lumacaftor 200 mg/ivacaftor 125 mg) for the treatment of cystic fibrosis (CF) in patients 12 years and older who have the F508del mutation. Having two copies of this mutation is the leading cause of CF. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares